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Abstract
Background: MANTICORE 101 - Breast (Multidisciplinary Approach to Novel Therapies in Cardiology Oncology
Research) is a randomized trial to determine if conventional heart failure pharmacotherapy (angiotensin converting
enzyme inhibitor or beta-blocker) can prevent trastuzumab-mediated left ventricular remodeling, measured with
cardiac MRI, among patients with HER2+ early breast cancer.
Methods/Design: One hundred and fifty-nine patients with histologically confirmed HER2+ breast cancer will be
enrolled in a parallel 3-arm, randomized, placebo controlled, double-blind design. After baseline assessments,
participants will be randomized in a 1:1:1 ratio to an angiotensin-converting enzyme inhibitor (perindopril), beta-
blocker (bisoprolol), or placebo. Participants will receive drug or placebo for 1 year beginning 7 days before
trastuzumab therapy. Dosages for all groups will be systematically up-titrated, as tolerated, at 1 week intervals for a
total of 3 weeks. The primary objective of this randomized clinical trial is to determine if conventional heart failure
pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early
breast cancer, as measured by 12 month change in left ventricular end-diastolic volume using cardiac MRI.
Secondary objectives include 1) determine the evolution of left ventricular remodeling on cardiac MRI in patients
with HER2+ early breast cancer, 2) understand the mechanism of trastuzumab mediated cardiac toxicity by
assessing for the presence of myocardial injury and apoptosis on serum biomarkers and cardiac MRI, and 3)
correlate cardiac biomarkers of myocyte injury and extra-cellular matrix remodeling with left ventricular remodeling
on cardiac MRI in patients with HER2+ early breast cancer.
Discussion: Cardiac toxicity as a result of cancer therapies is now recognized as a significant health problem of
increasing prevalence. To our knowledge, MANTICORE will be the first randomized trial testing proven heart failure
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any medium, provided the original work is properly cited.pharmacotherapy in the prevention of trastuzumab-mediated cardiotoxicity. We expect the findings of this trial to
provide important evidence in the development of guidelines for preventive therapy.
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Background
Breast cancer is the most common malignancy and sec-
ond leading cause of cancer death [1]. Approximately
20-25% of breast cancers over-express human epidermal
growth factor receptor 2 (HER2+) which is associated
with poor prognosis [2,3]. Trastuzumab (Herceptin
®), a
humanized monoclonal antibody targeting the HER2
receptor, was previously shown to improve survival by
20% in women with HER2+metastatic disease [4-7].
More recently, 4 major adjuvant trials of women with
HER2+ early breast cancer (EBC) demonstrated that
trastuzumab reduced 3-year breast cancer recurrence
and risk of death rate by 50% [8]. Given these positive
findings, trastuzumab was approved in 2006 by the Food
and Drug Administration for the adjuvant treatment of
HER2+ breast cancer.
Despite favourable survival benefits, an adverse effect
of trastuzumab is (a)symptomatic left ventricular (LV)
dysfunction and heart failure (HF). In the phase III
trials, HF and asymptomatic LV dysfunction was
reported in 4% and 18% of patients, respectively [9-11].
Although trastuzumab-related cardiotoxicity has been
considered ‘reversible’ [12], Wadhwa et al. reported that
trastuzumab was stopped in 22% of patients due to
asymptomatic LV systolic dysfunction; notably, of these,
40% showed no improvement or worsening of LV func-
tion over time despite optimal pharmacotherapy [13].
Similarly, Chia observed that 21.6% of women receiving
adjuvant trastuzumab-based chemotherapy experienced
a cardiac event requiring temporary or permanent dis-
continuation of trastuzumab [14]. These observations
are important, given the influence of more stringent car-
diac exclusion criteria in the pivotal trials compared to
standard clinical practice. Furthermore, any dose reduc-
tions, delay or discontinuation due to cardiotoxicity are
potentially life-threatening events from the competing
risks of cancer and/or cardiac mortality. Therefore, bet-
ter understanding of the pathophysiology of trastuzu-
mab-mediated cardiotoxicity and its prevention are
urgently required.
Ventricular remodeling (increased cavity size and
decreased pump function) precedes overt HF [15-17].
Our group has shown that aerobic exercise training has
beneficial anti-remodeling benefits in clinically stable
systolic HF patients [18]. Based on these findings, we
examined the effect of 4 months of aerobic exercise
training on LV remodeling in 17 women with EBC
receiving trastuzumab-based chemotherapy [19]. We
found that LV remodeling occurs early, confirming
observations of other groups [14,20], and that an early
exercise intervention did not attenuate remodeling in
this setting. Accordingly, we identified the need for
examination of non-exercise interventions.
Pharmacotherapy has been shown to attenuate or
reverse LV remodeling in the HF and post-myocardial
infarction (MI) setting. Angiotensin-converting enzyme
inhibitors (ACEI) have been proven to delay or reverse
LV dilation and improve ejection fraction (EF) in multi-
ple trials [21-24]. Beta-blockers (BB) have also been
shown to be beneficial, but have largely been tested in
combination with other therapies [25,26]. To date, a
paucity of studies have examined conventional HF ther-
apy during anthracycline therapy [27-29]. Specifically,
carvedilol has been shown to be an effective single-agent
therapy in anthracycline-induced cardiomyopathy [30].
Cardinale et al demonstrated that an ACEI can prevent
a decline in EF and cardiac events in cancer patients
receiving high dose anthracyclines [31]. In general, how-
ever, preventive medical therapy is not considered
necessary with anthracycline-based regimens, as toxicity
is related to the cumulative dose (> 500 mg/m
2) [32].
Detection and measurement of LV dysfunction may be
hampered by insensitivity of routinely-available imaging
modalities. Most EBC clinical trials have employed
either radionuclide ventriculography (eg. MUGA) or
transthoracic echocardiograms (ECHO) which may
underestimate LV volumes [33]. Cardiac MRI is the pre-
ferred method for the quantification of ventricular
volumes and EF in individuals with impaired LV systolic
function [34-36]. Unfortunately, relying on a decline in
EF or overt clinical symptoms limits detection of cardio-
toxicity to the late stage of disease process, increasing
the likelihood of irreversible myocardial damage.
In addition to detailed imaging, cardiac biomarkers
may contribute to early detection, assessment and
longer-term monitoring of cardiotoxicity. In patients
with multiple types of advanced cancer receiving high-
dose chemotherapy, Cardinale and associates demon-
strated that troponin I increased in one-third of patients
shortly after treatment, which was associated with a
concomitant reduction in EF within the subsequent
year [31]. In serial evaluation of adjuvant and metastatic
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vations in troponin were seen early in therapy (after 2
cycles) and with adjustment for major confounders, was
the strongest independent predictor of future EF decline,
occurring within 1 - 8 months [37]. In these patients (n
= 42), a three-fold decrease in likelihood of recovery
was observed over time despite optimal pharmacother-
apy. Brain natriuretic peptide (BNP), an established mar-
ker of heart failure, has also been shown to predict
cardiac events including symptomatic heart failure,
arrhythmias and acute coronary syndrome in patients
receiving anthracycline-based chemotherapy [38]. While
these studies provide valuable insights, larger studies in
homogeneous patient groups with similar chemotherapy
regimens and biomarker collection are required before
general recommendations can be implemented [39].
Finally, other novel markers may have the potential to
detect early cardiac dysfunction. For example, collagen-
derived peptides have been correlated to the fractional
volume of myocardial fibrosis in hypertensive
patients [40]and HF[41]. As the underlying collagen-
based structure of the heart remodels, peptides are
released into the plasma [42-44]. While these molecules
have not been studied in cancer patients [45], prospec-
tive exploration of these markers and other prospec-
tively-collected biofluids may provide insight into
disease evolution or effects of pharmacotherapy.
To date, no study has prospectively examined the
effects of proven HF therapy to prevent cardiotoxicity in
patients with EBC receiving trastuzumab. The median
follow-up of the pivotal trastuzumab trials remains
between two and three years, limiting understanding of
the clinical course of patients with trastuzumab
mediated cardiac toxicity and thus, the appropriate
length of therapy. Therefore, the logical extension of
our body of research is to examine: (1) the underlying
pathogenesis of trastuzumab mediated cardiac toxicity,
(2) screening tools for detecting early LV remodeling in
this patient group, (3) determine the evolution of LV
remodeling beyond chemotherapy, and (4) pharma-
cotherapies to prevent LV remodeling for these patients.
Given this background, our cardio-oncology research
group designed the Multidisciplinary Approach to Novel
Therapies In Cardiology Oncology Research (MANTI-
CORE) trial. The primary objective of this randomized
clinical trial is to determine if conventional heart failure
pharmacotherapy (ACEI or BB) can prevent trastuzu-
mab-mediated LV remodeling among patients with
HER2+ EBC, determined by 12 month change in LV
end-diastolic volume (LVEDV) measured using cardiac
MRI. Secondary objectives include 1) determine the evo-
lution of LV remodeling on cardiac MRI in patients with
HER2+ EBC; 2) understand the mechanism of trastuzu-
mab mediated cardiac toxicity by assessing for the
presence of myocardial injury and apoptosis using
serum biomarkers and cardiac MRI; and 3) correlate
cardiac biomarkers of myocyte injury and extra-cellular
matrix remodeling with LV remodeling on cardiac MRI.
Methods/Design
This study is parallel 3-arm, randomized, placebo con-
trolled, double-blind study comparing bisoprolol and
perindopril for the prevention of LV remodeling in
patients with HER2+ breast cancer treated with adjuvant
trastuzumab. Additional inclusion requirements are ade-
quate creatinine clearance, age > 18 years, no contrain-
dication to MRI and willingness to provide informed
consent. Exclusion criteria are known contraindication
or current treatment with ACEI or BB; history of heart
failure, cardiomyopathy, baseline EF < 50%; and history
of uncontrolled hypertension or myocardial infarction.
Ethical approval has been secured from the two relevant
institutional review Boards.
Participants and Setting
Potential participants are consecutively identified and
screened for eligibility by the study coordinator during
multidisciplinary Tumor Board review of all new breast
cancer case consultations. Following primary oncologist
approval, potential participants are provided with a
review of the study and provided with written study
information. After obtaining written consent, partici-
pants will be scheduled for a baseline clinic visit for
final determination of eligibility.
Group Allocation
Participants will be randomized in a 1:1:1 ratio to peri-
ndopril, bisoprolol, or placebo (Figure 1) using a secure
internet randomization service (EPICORE, http://www.
epicore.ualberta.ca).
N = 159 (53 per arm)
R
perindopril
bisoprolol
placebo
Figure 1 Randomization Randomization Scheme Diagram
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Participants will receive drug or placebo for 1 year
beginning 7 days before trastuzumab therapy. There
will be no run-in period. Dosages for all groups will be
systematically up-titrated as tolerated at 1 week inter-
vals, for a total of 3 weeks. Perindopril will be initiated
at 2 mg and titrated to a target dose of 8 mg. Bisopro-
lol will be initiated at 2.5 mg and titrated to a 10 mg
target dose. All dosages will be labeled by dose level
(1, 2 or 3) and will be otherwise identical in
appearance.
Blinding and Masking
The study coordinator, investigators, treating oncolo-
gists and patient will all be blinded to drug allocation
and outcomes. All cardiac MRIs will be read by a core
lab at the Mazankowski Alberta Heart Institute
(MAHI) in Edmonton, Canada, with 2 readers, blinded
to treatment allocation. The treating oncologist will be
provided with global EF measurement only (per stan-
dard of care).
Evaluations
Baseline demographics, medical history, cardiac risk fac-
tors, and cardiac history are evaluated. Physical exami-
nation including cardiovascular exam, blood pressure
and pulse is performed. Blood is collected for the pur-
poses of measuring baseline electrolytes, creatinine (for
estimation of glomerular filtration rate [GFR]), and bio-
markers (Figure 2) and an electrocardiogram. Partici-
pants undergo a comprehensive baseline cardiac MRI as
part of their routine pre-chemotherapy ventricular func-
tion evaluation in lieu of conventional modalities. An
additional consent is obtained for prospective serial col-
lection of serum and urine in the Alberta Research
Tumor Bank (http://www.abtumorbank.com) for future
analysis.
Participants initiate study drug one week prior to
starting trastuzumab therapy and are scheduled for titra-
tion visits (Figure 2). Participants return for a visit with
the study coordinator at 3 and 12 months after rando-
mization to be assessed for signs and symptoms of HF,
major adverse cardiac events (MACE), adverse effects
assessment* 
MRI 
biomarkers
0 1 3 6 9 12 24mos
trastuzumab
Randomization
telephone
follow-up
medication
titration
7d 14d
assessment*
MRI 
biomarkers
assessment* 
MRI 
biomarkers
assessment* 
MRI 
biomarkers
*assessment = history, physical, labs
** or placebo
Bisoprolol**
Perindopril**
2.5mg 5 10
2mg 4 8 telephone
follow-up
21d
telephone
follow-up
18
Figure 2 Study Procedures Flow Diagram of Study Procedures
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medication. In addition, participants will be contacted
by telephone at months 1, 6, 9 and 18 to ensure contin-
ued stability and minimize loss to follow-up. Participants
will also undergo blood work to assess electrolytes and
creatinine at 3 month intervals as per routine care while
on trastuzumab therapy and have biomarkers drawn at
3 and 12 months for comparison with the concurrent
cardiac MRI measures. Cardiac monitoring at 6 and 9
month intervals will be performed with routinely avail-
able modalities per standard of care. If trastuzumab
therapy is discontinued due to cardiac toxicity outside
of the 3 or 12 month cardiac MRI scans then partici-
pants will return for another clinically indicated cardiac
MRI within 1 week of chemotherapy termination.
Participants will return for a final visit with the study
coordinator at 24 months, or 1 year after trastuzumab
therapy termination. The study coordinator will perform
t h es a m ec l i n i c a la s s e s s m e n t as on previous follow-up
visits at 3 and 12 months. Evaluation of medications will
be done to ascertain if treatment for HF has been
initiated since the 12 month visit. Patients will undergo
the same collection of serum biomarkers. A non-clini-
cally indicated research cardiac MRI will be performed
to assess for the presence of ongoing LV remodeling.
The long-term cardiac implications of trastuzumab ther-
apy are unknown but we hypothesize that the exposed
heart will be more vulnerable to future insults [49].
Data Security
De-identifying case report form development, data entry,
quality assurance and data analysis will be performed by
EPICORE. De-identified image data from cardiac MRIs
will be stored on a secure network using unique identi-
fiers. Blood samples for biomarker analysis will also only
be identified by unique identifiers and stored for batch
analysis.
Statistical Considerations
Outcome analyses
Participants will be analyzed with the intention to treat
principle. The primary outcome analysis will be the dif-
ference in mean change in LVEDV at 1 year in each
active treatment arm and the placebo arm, evaluated
using a general linear model controlling for differences
in patient characteristics at the baseline and 12 month
assessments. A general linear mixed model will be used
to assess group differences with serial correlation over
time based on the baseline, 3, 12, and 24 month mea-
surements with correlated post-hoc analysis where
appropriate. All statistical tests will be two-sided.
Regression analyses and diagnostic tests will be per-
formed to model changes in continuous variables from
imaging with those from biomarker measures. Statistical
significance will be assumed at the 5% level (p < 0.05).
Missing data will be interpolated where possible using
multivariable imputation. Data will be analyzed using
SAS 9.2 (SAS, Cary, NC) software.
Sample size calculations
Based on our pilot data [19], we expect the placebo
g r o u pw i l lh a v eam i n i m u mc h a n g ei nL V E D Vo f+ 1 1 %
with 1-year of trastuzumab therapy. We assume that
pharmacotherapy with ACEI would prevent 90% of the
trastuzumab mediated remodeling as measured by a
change in LVEDV at 1 year = +1%. As previously men-
tioned, ACEI and perindopril have been shown to
entirely prevent LV remodeling in other models of heart
failure. Note that the change in LV volume in our pilot
study was observed after 4 months of trastuzumab;
hence we are possibly underestimating the true magni-
tude of change in LV volume at 1 year in the placebo
g r o u po ft h i ss t u d y .T h i si ss u p p o r t e db ya ni n t e r i m
analysis of the BCIRG 006 trial, showing that mean LV
function tended to decrease out to 8 months regardless
of the chemotherapy protocol [11]. If the within-group
standard deviation is 20 ml, with a two-2-tailed signifi-
cance level ∝ = 0.05 and a power of .80, then 47 partici-
pants are required for each group. We anticipate a 10%
drop-out rate and a 3% mortality rate during our 2 year
follow-up [46], therefore we will recruit a total 159 par-
ticipants. If the absolute difference between the mean
LVEDV in placebo and ACE inhibitor groups is greater
than 10% at 1 year, this sample size will still be suffi-
ciently powered to detect a lower degree of remodeling
prevention (Table 1).
Tracking and Monitoring of Adverse Events
Participants in this trial will be exposed to the known
risks of HF therapy however, follow-up visits, blood-
work and phone calls will screen for potential adverse
reaction. Cardiac MRI is a safe imaging modality with
no radiation exposure to patients. Gadolinium contrast
agents are now recognized to be associated with a rare
life threatening condition called nephrogenic systemic
fibrosis (NSF) however this complication is confined to
Table 1 Sample size calculations and magnitude of
difference in left ventricular remodeling between
treatment groups
Placebo
Δ LVEDV
at 1 year
Perindopril
Δ LVEDV
at 1 year
% Remodeling prevented
+11% +1% 90%
+11.7% +1.9% 84%
+12.5% +2.75% 78%
+14.2% +4.4% 69%
+15.8% +6.1% 62%
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Page 5 of 8those with GFR < 30 ml/min, an exclusion criterion of
our study.
EPICORE will oversee an independent data safety and
monitoring committee that will meet at quarterly inter-
vals and review MACE to ensure that continuation of the
study is safe. In the event that the participant will not be
able to continue either the study drug or placebo, they
will remain in their randomized group to preserve the
intention-to-treat principle. Indications for open label
therapy ACEI or BB therapy will include: (1) an absolute
decline in EF by ≥ 5% and EF < 55% with symptoms of
HF or (2) an asymptomatic absolute decline in EF by ≥
10% and EF < 50%. Participants are free to withdraw at
any time but will be invited to continue in their treat-
ment arm for the duration of the study.
Discussion
Methodological Considerations
Given our small sample size, we do not expect to find a
significant decrease in cardiac clinical outcomes, how-
ever, given the overwhelming evidence of clinical effi-
cacy in the HF literature, we expect to demonstrate a
beneficial effect of pharmacotherapy in preventing tras-
tuzumab-mediated LV remodeling. Our results would
then justify a multicenter trial studying the role of ACEI
and/or BB for preventing clinical HF and improving
long-term outcomes of breast cancer survivors. Further-
more, if ACEI or BB are proven efficacious in the pre-
vention of cardiac toxicity, then patients with known
cardiac dysfunction (thus ineligible to receive trastuzu-
mab) could also be studied. Effective strategies for pre-
venting trastuzumab mediated cardiac toxicity would
allow more HER2+ breast cancer patients to successfully
complete their adjuvant chemotherapy, while avoiding
delays or discontinuation of vital therapy.
Our secondary objectives may also yield information
on appropriate biomarkers to screen for cardiac toxicity
and provide additional infor m a t i o no nt h eu n d e r l y i n g
pathogenesis and the evolution of cardiac injury beyond
exposure to trastuzumab. Ideal biomarkers in this field
have yet to be identified, however, cardiac MRI allows
for precise characterization of LV dysfunction against
which biomarkers can be evaluated. In future studies,
we will analyze prospectively collected biofluids in the
study of metabolics and genomics of trastuzumab-
related cardiotoxicity. Urine metabolomics have the
capacity to sensitively measure metabolic processes at
the cellular level, and may provide early insights into
myocyte structural or energetic changes [47,48]. Mole-
cular profiling may identify key pathways involved in tis-
sue regeneration, drug metabolism and cell death
[49,50]; in studying copy number variants, we have
shown that toxicities associated with docetaxel-contain-
ing chemotherapy regimens may be predicted [51].
Taken together, study of biomarkers and clinical out-
comes in this setting will contribute to personalized care
and improved therapeutic outcomes.
Conclusion
Cardiac toxicity as a result of cancer therapies is now
recognized as a significant health problem of increasing
prevalence. While therapies such as trastuzumab poten-
tially offer improved survival with targeted anti-tumor
activities, the additional cardiac insult in addition to ‘mul-
tiple-hit’ [52] injuries put patients at risk of morbidity and
potentially premature mortality. A limitation of the exist-
ing data is that the median follow-up in the trastuzumab
adjuvant trials is between 2 and 3 years. Therefore, infor-
mation is lacking on the potential for late cardiac dysfunc-
tion, or whether short-term improvements in LV
remodeling or EF with medical treatment are permanent
or temporary. Future trials with longer follow-up are
necessary to address these remaining issues.
To our knowledge, MANTICORE will be the first ran-
domized trial testing proven HF pharmacotherapy in the
prevention of trastuzumab-mediated cardiotoxicity. We
expect the findings of this trial to provide high-level evi-
dence in the development of guidelines for preventive
therapy. Relationships of established and novel biomar-
kers to sensitive MRI measures will enhance our under-
standing of these markers, as well as development of
sensitive assays for the earliest detection of cardiovascu-
lar changes in these patients. Lastly, this work will
inform and support other long-term goals of our team,
in the prevention, detection and treatment of cardiovas-
cular effects of cancer therapies.
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